Aurobindo partially halts production at Eugia’s Unit-III formulations facility after 9 USFDA observations

Aurobindo Pharma temporarily halts certain manufacturing lines at the Pashamylaram formulations facility in Hyderabad, following nine USFDA observations. The observations were issued after the US regulatory authority inspected the Eugia facility from Jan 22 to Feb 2, 2024. Aurobindo Pharma is working with regulatory authorities to investigate and resume production on those lines.

from Hyderabad News: Latest Hyderabad News Headlines & Live News Updates from Hyderabad - Times of India https://ift.tt/IxfZ2tW